Concept for a study design in patients with severe community-acquired pneumonia: A randomised controlled trial with a novel IGM-enriched immunoglobulin preparation - The CIGMA study

Respiratory Medicine

Volumn 109, Issue 6, 2015, Pages 758-767

  Welte, Tobias ^a   Dellinger, R Phillip ^b   Ebelt, Henning ^c   Ferrer, Miquel ^d   Opal, Steven M ^e   Schliephake, Dorothee E ^f   Wartenberg Demand, Andrea ^f   Werdan, Karl ^g   Löffler, Kurt ^h   Torres, Antoni ^d  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b Cooper Medical School of Rowan University ^*  (United States)

^c St Nepomuk Hospital   (Germany)

^d HOSPITAL CLÍNIC   (Spain)

^e BROWN UNIVERSITY   (United States)

^f BIOTEST AG   (Germany)

^g MARTIN LUTHER UNIVERSITÄT HALLE WITTENBERG   (Germany)

^h ACCOVION GMBH   (Germany)

Author keywords

Adjunctive therapy; BT086; IgM enriched immunoglobulins; Mechanically ventilated; Severe community acquired pneumonia; Ventilator free days

Indexed keywords

BT 086; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; PLACEBO; UNCLASSIFIED DRUG;

ARTICLE; ARTIFICIAL VENTILATION; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ENDOTRACHEAL INTUBATION; EXTUBATION; HUMAN; MAJOR CLINICAL STUDY; MECHANICAL VENTILATOR; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; AGED; BLOOD; CLINICAL TRIAL; COMMUNITY-ACQUIRED INFECTIONS; FEMALE; FOLLOW UP; MALE; PASSIVE IMMUNIZATION; PNEUMONIA, BACTERIAL; PROCEDURES; TREATMENT OUTCOME; VENTILATOR WEANING; VERY ELDERLY;

AGED; AGED, 80 AND OVER; COMMUNITY-ACQUIRED INFECTIONS; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOGLOBULIN M; MALE; PNEUMONIA, BACTERIAL; TREATMENT OUTCOME; VENTILATOR WEANING;

EID: 84930400090     PISSN: 09546111     EISSN: 15323064     Source Type: Journal    
DOI: 10.1016/j.rmed.2015.03.008     Document Type: Article

References (53)

1. J.G. Bartlett, S.F. Dowell, L.A. Mandell, T.M. File Jr., D.M. Musher, and M.J. Fine Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America Clin Infect Dis 31 2000 347 382 10.1086/313954
2. O. Sibila, M.I. Restrepo, and A. Anzueto What is the best antimicrobial treatment for severe community-acquired pneumonia (including the role of steroids and statins and other immunomodulatory agents)? Infect Dis Clin North Am 27 2013 133 147 10.1016/j.idc.2012.11.014
3. T. Welte, A. Torres, and D. Nathwani Clinical and economic burden of community-acquired pneumonia among adults in Europe Thorax 67 2012 71 79 10.1136/thx.2009.129502
4. M.S. Niederman Community-acquired pneumonia: the US perspective Semin Respir Crit Care Med 30 2009 179 188 10.1055/s-0029-1202937
5. S. Ewig, and A. Torres Community acquired pneumonia as an emergency: time for an aggressive intervention to lower mortality Eur Respir J 38 2011 253 260 10.1183/09031936.00199810
6. J.J. Oosterheert, M.J. Bonten, E. Hak, M.M. Schneider, and A.I. Hoepelman Severe community-acquired pneumonia: what's in a name? Curr Opin Infect Dis 16 2003 153 159 10.1097/01.aco.0000065082.06965.14
7. M. Woodhead, C.A. Welch, A.H. David, B. Geoff, and G.A. Jon Community-acquired pneumonia on the intensive care unit: secondary analysis of 17,869 cases in the ICNARC Case Mix Programme Database Crit Care 10 2006 S1 10.1186/cc4927
8. R.G. Wunderink, P.F. Laterre, B. Francois, D. Perrotin, A. Artigas, L.O. Vidal CAPTIVATE Trial Group Recombinant tissue factor pathway inhibitor in severe community-acquired pneumonia: a randomized trial Am J Respir Crit Care Med 183 2011 1561 1568 10.1164/rccm.201007-1167OC
9. J.M. Sirvent, M. Carmen de la Torre, C. Lorencio, A. Taché, C. Ferri, and J. Garcia-Gil Predictive factors of mortality in severe community-acquired pneumonia: a model with data on the first 24h of ICU admission Med Intensiva 37 2013 308 315 10.1016/j.medin.2013.03.003
10. C. Cillóniz, S. Ewig, E. Polverino, M.A. Marcos, C. Esquinas, and A. Gabarrús Microbial aetiology of community-acquired pneumonia and its relation to severity Thorax 66 2011 340 346 10.1136/thx.2010.143982
11. J.P. Lynch 3rd, and G.G. Zhanel Escalation of antimicrobial resistance among Streptococcus pneumoniae: implications for therapy Semin Respir Crit Care Med 26 2005 575 616 10.1055/s-2005-925524
12. J.A. Kellum, L. Kong, M.P. Fink, L.A. Weissfeld, D.M. Yealy, and M.R. Pinsky Understanding the inflammatory cytokine response in pneumonia and sepsis: results of the Genetic and Inflammatory Markers of Sepsis (GenIMS) Study Arch Intern Med 167 2007 1655 1663
13. G.R. Bernard, J.L. Vincent, P.F. Laterre, S.P. LaRosa, J.F. Dhainaut, and A. Lopez-Rodriguez Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. Efficacy and safety of recombinant human activated protein C for severe sepsis N Engl J Med 344 2001 699 709 10.1056/NEJM200103083441001
14. V.M. Ranieri, B.T. Thompson, P.S. Barie, J.F. Dhainaut, I.S. Douglas, and S. Finfer Drotrecogin alfa (activated) in adults with septic shock N Engl J Med 366 2012 2055 2064 10.1056/NEJMoa1202290
15. M. Confalonieri, M. Kodric, M. Santagiuliana, C. Longo, M. Biolo, and R. Cifaldi To use or not to use corticosteroids for pneumonia? A clinician's perspective Monaldi Arch Chest Dis 77 2012 94 101
16. S.C. Meijvis, H. Hardeman, H.H. Remmelts, R. Heijligenberg, G.T. Rijkers, and H. van Velzen-Blad Dexamethasone and length of hospital stay in patients with community-acquired pneumonia: a randomised, double-blind, placebo-controlled trial Lancet 377 2011 2023 2030 10.1016/S0140-6736(11)60607-7
17. J.I.F. Salluh, P. Póvoa, M. Soares, H.C. Castro-Faria-Neto, F.A. Bozza, and P.T. Bozza The role of corticosteroids in severe community acquired pneumonia: a systematic review Crit Care 12 2008 R76 10.1186/cc6922
18. C.L. Sprung, D. Annane, D. Keh, R. Moreno, M. Singer, K. Freivogel CORTICUS Study Group Hydrocortisone therapy for patients with septic shock N Engl J Med 358 2008 111 124 10.1056/NEJMoa071366
19. S.M. Opal, P.F. Laterre, B. Francois, S.P. LaRosa, D.C. Angus, and J.P. Mira Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial JAMA 309 2013 1154 1162 10.1001/jama.2013.2194
20. F. Esen, and S. Tugrul IgM-enriched immunoglobulins in sepsis J.L. Vincent, Intensive care medicine annual update 2009 Springer-Verlag New York 102 110 Section III
21. M. Trautmann, T.K. Held, M. Susa, M.A. Karajan, A. Wulf, and A.S. Cross Bacterial lipopolysaccharide (LPS)-specific antibodies in commercial human immunoglobulin preparations: superior antibody content of an IgM-enriched product Clin Exp Immunol 111 1998 81 90
22. N.D. Garbett, C.S. Munro, and P.J. Cole Opsonic activity of a new intravenous immunoglobulin preparation: Pentaglobin compared with Sandoglobulin Clin Exp Immunol 76 1989 8 12
23. W. Stephan Investigations to demonstrate the antibacterial and antitoxic efficacy of an IgM-enriched intravenous immunoglobulin preparation E. Faist, J. Ninnemann, D. Green, Immune consequences of trauma; shock and sepsis 1989 Springer-Verlag Heidelberg 501 507
24. R. Rieben, A. Roos, Y. Muizert, C. Tinguely, A.F. Gerritsen, and M.R. Daha Immunoglobulin M-enriched human intravenous immunoglobulin prevents complement activation in vitro and in vivo in a rat model of acute inflammation Blood 93 1999 942 951
25. M.R. Ehrenstein, and C.A. Notley The importance of natural IgM: scavenger, protector and regulator Nat Rev Immunol 10 2010 778 786 10.1038/nri2849
26. K.G. Kreymann, G. de Heer, A. Nierhaus, and S. Kluge Use of polyclonal immunoglobulins as adjunctive therapy for sepsis or septic shock Crit Care Med 35 2007 2677 2685 10.1097/01.CCM.0000295263.12774.97
27. M.M. Alejandria, M.A. Lansang, L.F. Dans, and J.B. Mantaring 3rd Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock Cochrane Database Syst Rev 9 2013 CD001090 10.1002/14651858.CD001090.pub2
28. K. Werdan, G. Pilz, O. Bujdoso, P. Fraunberger, G. Neeser, and R.E. Schmieder Score-based immunoglobulin G therapy of patients with sepsis: the SBITS study Crit Care Med 35 2007 2693 2701 10.1097/01.CCM.0000295426.37471.79
29. K. Reinhart, F.M. Brunkhorst, H.-G. Bone, J. Bardutzky, C.-E. Dempfle, and H. Forst Prevention, diagnosis, therapy and follow-up care of sepsis: 1st revision of S-2k guidelines of the German Sepsis Society (Deutsche Sepsis-Gesellschaft e.V. (DSG)) and the German Interdisciplinary Association of Intensive Care and Emergency Medicine (Deutsche Interdisziplinäre Vereinigung für Intensiv- und Notfallmedizin (DIVI)) Ger Med Sci 8 2010 10.3205/000103 Doc 14
30. G. Berlot, M.C. Vassallo, N. Busetto, M. Bianchi, F. Zornada, and I. Rosato Relationship between the timing of administration of IgM and IgA enriched immunoglobulins in patients with severe sepsis and septic shock and the outcome: a retrospective analysis J Crit Care 27 2012 167 171 10.1016/j.jcrc.2011.05.012
31. M.C. de la Torre, I. Bolíbar, M. Vendrell, J. de Gracia, E. Vendrell, and M.J. Rodrigo Serum immunoglobulins in the infected and convalescent phases in community-acquired pneumonia Respir Med 107 2013 2038 2045 10.1016/j.rmed.2013.09.005
32. M. Justel, L. Socias, R. Almansa, P. Ramírez, M.C. Gallegos, and V. Fernandez IgM levels in plasma predict outcome in severe pandemic influenza J Clin Virol 58 2013 564 567 10.1016/j.jcv.2013.09.006
33. M. Päsler, S. Dietz, and K. Werdan Hypogammaglobulinemia in sepsis J.L. Vincent, Annual update in intensive care and emergency medicine 2012 Springer-Verlag Berlin Heidelberg 98 108 10.1007/978-3-642-25716-2
34. E.J. Giamarellos-Bourboulis, E. Apostolidou, M. Lada, I. Perdios, N.K. Gatselis, and I. Tsangaris Kinetics of circulating immunoglobulin M in sepsis: relationship with final outcome Crit Care 17 2013 R247 10.1186/cc13073
35. S. Schmiedl, J. Szymanski, A. Wartenberg-Demand, A. Remy, and P. Thuerman Evaluation of pharmacokinetics and safety of the IgM enriched immunoglobulin concentrate BT086 in healthy volunteers - results of a dose escalating single dose phase I study Br J Clin Pharmacol 72 2011 21 abstract 40
36. S. Schmiedl, J. Szymanski, A. Wartenberg Demand, and P. Thuerman Evaluation of pharmacokinetics and safety of the IgM enriched immunoglobulin concentrate BT086 in healthy volunteers - results of a multiple dose phase I study Br J Clin Pharmacol 72 2011 1 46 abstract 43
37. L.A. Mandell, R.G. Wunderink, A. Anzueto, J.G. Bartlett, G.D. Campbell, and N.C. Dean Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults Clin Infect Dis 44 2007 S27 S72 10.1086/511159
38. U.S. Department of Health and Human Services, Food and Drug Administration Guidance for industry. community-acquired bacterial pneumonia: developing drugs for treatment Revision 2 January 2014 Center for Drug Evaluation and Research (CDER)
39. G. Höffken, L. Lorenz, W. Kern, T. Welte, T. Bauer, and K. Dalhoff Epidemiology, diagnosis, antimicrobial therapy and management of community-acquired pneumonia and lower respiratory tract infections in adults. Guidelines of the Paul-Ehrlich-Society for Chemotherapy, the German Respiratory Society, the German Society for Infectiology and the Competence Network CAPNETZ Germany [Article in German] Pneumologie 63 2009 e1 e68 10.1055/s-0029-1215037
40. A. Rodríguez, J. Rello, J. Neira, B. Maskin, D. Ceraso, and L. Vasta Effects of high-dose of intravenous immunoglobulin and antibiotics on survival for severe sepsis undergoing surgery Shock 23 2005 298 304 10.1097/01.shk.0000157302.69125.f8
41. A. Esan, D. Hess, C. Sessler, L. George, C. Oribabor, and F. Khusid Ventilator strategies in severe hypoxaemic respiratory failure Eur Respir Mon 55 2012 19 39
42. N.R. MacIntyre The ventilator discontinuation process: an expanding evidence base Respir Care 58 2013 1074 1082 10.4187/respcare.02284
43. A.W. Thille, J.C. Richard, and L. Brochard The decision to extubate in the intensive care unit Am J Respir Crit Care Med 187 2013 1294 1302 10.1164/rccm.201208-1523CI
44. L. Acion, J.J. Peterson, S. Temple, and S. Arndt Probabilistic index: an intuitive non-parametric approach to measuring the size of treatment effects Stat Med 25 2006 591 602 10.1002/sim.2256
45. W. Lehmacher, and G. Wassmer Adaptive sample size calculations in group sequential trials Biometrics 55 1999 1286 1290
46. G.E. Noether Sample size determination for some common nonparametric statistics J Am Stat Assoc 82 1987 645 647
47. J. Elashoff nQuery Advisor® Version 7.0 User's Guide 2007 Los Angeles, California, USA
48. Wassmer and Eisebitt ADDPLAN Adaptive Designs - Plans and Analyses® User's Guide, Release 5.0 2009 ADDPLAN GmbH Cologne
49. J.L. Vincent, and M. Van Nuffelen Septic shock: new pharmacotherapy options or better trial design? Expert Opin Pharmacother 14 2013 561 570 10.1517/14656566.2013.777429
50. P.F. Laterre, G. Garber, H. Levy, R. Wunderink, G.T. Kinasewitz, and J.P. Sollet Severe community-acquired pneumonia as a cause of severe sepsis: data from the PROWESS study Crit Care Med 33 2005 952 961 10.1097/01.CCM.0000162381.24074.D7
51. G.A. Ospina-Tascón, G.L. Büchele, and J.L. Vincent Multicenter, randomized, controlled trials evaluating mortality in intensive care: doomed to fail? Crit Care Med 36 2008 1311 1322 10.1097/CCM.0b013e318168ea3e
52. D.M. Arnold, and D.J. Cook The intensive care unit M. Kolb, C.F. Vogelmeier, Outcomes in clinical trials. European respiratory monograph 2013 85 89 10.1183/1025448x.10044912
53. D.A. Schoenfeld, and G.R. Bernard ARDS Network. Statistical evaluation of ventilator-free days as an efficacy measure in clinical trials of treatments for acute respiratory distress syndrome Crit Care Med 30 2002 1772 1777